EVCM

LLM Evaluations

Transcript Summary

EverCommerce reported Q1 2026 revenue of $147.5 million and adjusted EBITDA of $40.7 million, meeting or exceeding guidance. The company is aggressively transitioning to an 'AI-first' model, focusing on the EverPro and EverHealth verticals. Management showcased AI-driven efficiency gains, such as the ZyraTalk voice agent and EverHealth AI Scribe, which are designed to increase ARPU and customer retention. While overall revenue growth was 3.6%, the company's 'Top 6' solutions outperformed, with TPV growth near 20%. Multi-solution customer adoption remains a bright spot, growing 32% year-over-year. Financial headwinds included a 95% NRR due to legacy payment portfolio decay and the recent divestiture of the Marketing Technology segment. However, the company reiterated its 2026 full-year guidance, projecting a second-half acceleration fueled by pricing adjustments and AI monetization. Capital allocation included $13.9 million in share repurchases, with a stable 2.2x net leverage. EverCommerce aims to leverage its deep micro-vertical data to provide unique 'agentic' workflows for over 745,000 customers, positioning itself as a central operating system for service-based SMBs.

5-year share-count history (top 10 holders by peak, incl. exited) + price

Revenue Segments

Filing Risk Scores

EverCommerce Inc.: Aggressive Asset Capitalization and Governance Litigation Masked by AI Narrative

Full Earnings Call Transcript — Q1 • 2026-05-08

Operator: Thank you for standing by. Welcome to EverCommerce's First Quarter 2026 Earnings Call. My name is Victor, and I'll be your operator for today. [Operator Instructions] As a reminder, this conference call is being recorded today, May 7, 2026. And I would now like to turn the conference over to Brad Korch, Senior Vice President of Finance and Head of Investor Relations for EverCommerce. Please go ahead.
Bradley Korch: Good afternoon, and thank you for joining. Today's call will be led by Eric Remer, EverCommerce's Chairman and Chief Executive Officer; and Ryan Siurek, EverCommerce's Chief Financial Officer. Joining them will be Matt Feierstein, EverCommerce's President and the CEO of EverPro; and Evan Berlin, the CEO of EverHealth. This call is being webcast with a slide presentation that reviews the key financial and operating results for the 3 months ended March 31, 2026. For a link to the live or replay webcast, please visit the Investor Relations section of the EverCommerce website, www.evercommerce.com. The slide presentation and earnings release are also directly available on the site. Please turn to Page 2 of our earnings call presentation while I review our safe harbor statement. Statements made on this call and contained in the earnings materials available on our website that are not historical in nature may constitute forward-looking statements. Such statements are based on the current expectations and beliefs of management. Actual results may differ materially from these forward-looking statements due to risks and uncertainties that are described in more detail in our filings with the SEC. We undertake no obligation to publicly update or revise these forward-looking statements, except as required by law. We will also refer to certain non-GAAP financial measures in our comments today. A reconciliation of non-GAAP to GAAP historical measures is provided in both our earnings press release and our earnings call presentation. As a quick reminder, in Q3 of last year, we closed on the sale of the Marketing Technology business. Our commentary today will center on the continuing operations of our business focused on our EverHealth, EverPro and EverWell verticals. All financial and operating metric results and year-over-year comparisons are presented relating to continuing operations, except for cash flow metrics or unless otherwise specified. I will now turn it over to our CEO, Eric Remer. Please continue.
Eric Remer: Thank you, Brad. We had a strong start to the year, in line with expectations and focused on investing in key areas for accelerated growth in the back half of 2026 and beyond, including a focus on our continued integration of AI and go-to-market capabilities. Additionally, we continue to progress against our strategy of multi-solution adoption with emphasis on our top 6 solutions. During the first quarter, EverCommerce generated revenue of $147.5 million, above the midpoint of our guidance range, representing 3.6% year-over-year growth. Adjusted EBITDA for the quarter of $40.7 million exceeded the midpoint of our guidance range, representing a margin of 27.6%. Our cross-sell motion continues to expand. In the first quarter, we saw 32% growth in customers utilizing more than one solution. Finally, we repurchased 1.3 million shares for $13.9 million during the quarter while maintaining a stable leverage profile. EverCommerce is building the AI operating system for the service SMB workflows. We offer tremendous value to our customers by providing the system of actions necessary to run their business with tailored unique workflows. We provide end-to-end solutions to more than 745,000 customers across our 3 major verticals, EverPro for home and field services; EverHealth for medical practices and EverWell for wellness and service providers, with the 2 former verticals representing approximately 95% of consolidated revenue. Our large and growing customer base represents a significant embedded opportunity to expand value through integrated payments, intelligent automation and AI-driven workflows. On a pro forma basis, for the last 12 months, we generated $596 million of revenue, representing 5.2% year-over-year growth. We also generated 29.7% adjusted EBITDA margin on an LTM basis. Finally, our annualized total payment volume, or TPV, was $12.9 billion. We've often stated that our purpose of EverCommerce is to simplify and empower the lives of business owners whose services support us every day. This statement is as true today as it was when we founded the company, enabling our customers is at the center of everything we do, including many of the AI-first enhancements we discussed last quarter. AI is a force multiplier for our customers, providing a variety of growth opportunities and efficiencies. For us, there's also a tremendous opportunity to increase retention and ARPU. Along with our embedded payment opportunity, we believe this will result in revenue reacceleration. Because we view AI to be such an important value creation driver for our customers, we have transformed our own business with an AI-first focus. We are not just bolting on third-party capabilities for existing solutions, we are building native AI agentic features into our platforms. We are reimagining workflows and making significant investments to be at the leading edge of AI capabilities for our customers. As a reminder, our customers are small trades and small medical practices looking for simple yet vertically specific workflows needed to run their businesses. Our small business customers are not likely to vibe code their own solutions and the hands-on services our customers provide are not likely to replace with AI. Further, we believe our targeted deep micro vertical specific expertise and embedded base of more than 745,000 customers not only puts EverCommerce in the driver's seat to be the natural provider of agentic capabilities within the system of actions they already buy from us, but also provides us the rich micro vertical data to develop the best agentic platforms. On today's call, I'd like to now invite Matt and Evan to provide tangible examples of customer AI use cases in each EverPro and EverHealth.
Matthew Feierstein: Thanks, Eric. Let me highlight a quick example of how we're delivering value for customers through the EverPro platform using the Service Fusion product and the recently launched ZyraTalk AI integration. Coast-to-coast HTM is a medical equipment services company supporting hospital radiology departments across California and Texas. They operate under strict uptime requirements. When equipment goes down, speed is critical. Before Service Fusion, their operations were largely manual, spreadsheets for scheduling, limited system tracking and delays of up to 24 to 48 hours just to get approval to dispatch a technician. Now the team is seeing on-site mobilization within 4 to 6 hours. With Service Fusion, they centralized their operations and reduced time to get a technician on site from days down to just 4 to 6 hours, driving about a 50% efficiency gain in job management. Just as important, they're now managing compliance and audit requirements directly in the platform, which is critical in this business setting. At the beginning of this year, this customer expanded into AI with the addition of our ZyraTalk AI voice reception agent, adding an always-on communication layer that captures and documents every service request. Since deploying it, they've already booked over 30 jobs as a function of AI-driven interactions while also improving responsiveness and SLA tracking. This is the pattern we're seeing more broadly. Customers start with Service Fusion to run their operations, then add integrated AI voice reception to operate more efficiently and differentiate themselves in their market. This is a clear example of how customers expand from core workflow software into AI and automation, driving both higher retention and increased monetization over time. I will pass it over to Evan to discuss the EverHealth customer testimony.
Evan Berlin: Thanks, Matt. We're seeing similar adoption patterns across our health care base, where AI-driven documentation is improving provider efficiency while increasing the value of our platform. Let me share another example from EverHealth, this time in the clinical set. Our customer is a solo orthopedic surgeon based in Kansas City, who's been a DrChrono's customer for over a decade. Like many independent physicians, he's balancing the demands of running a highly specialized practice while also prioritizing his time outside of work. Before adopting our EverHealth AI Scribe, a significant portion of his day was spent on documentation, often hours after clinic, drafting and reviewing notes from patient visits. With our EverHealth AI Scribe integrated into DrChrono that dynamic has changed. Clinical notes that previously took hours are now completed in 10 minutes. And with the system accurately capturing complex orthopedic terminology and filtering out nonclinical conversation. This physician estimates savings of more than 1 hour per day with the added efficiency. And that's not just an efficiency gain. It's a meaningful improvement in his quality of life. He's able to finish his day on time, spend more time with family and stay focused on patient care instead of administrative work. Providers adopt DrChrono in their core clinical and operational system and then layer in AI capabilities like AI Scribe to reduce administrative burden, improve documentation quality and ultimately create more capacity in their practice. It's a powerful example of how our platform is not only improving efficiency, but also meaningfully improving the day-to-day experience of our customers and the care that they deliver to their patients.
Eric Remer: Thank you, Matt and Evan. One thing that both of these examples touched on is the importance of multiproduct adoption, which remain the key drivers for growth at EverCommerce. Multiproduct customers generate higher revenue, demonstrate stronger retention and expand wallet share over time. Historically, multiproduct adoption metrics were largely dominated by payments enablement, but AI feature adoption has increasingly become an important driver of customer value and ARPU as evidenced by the 2 customer stories we just shared. Our payment strategy focused on enabling payments at the point of initial SaaS sale while also driving cross-sell into our existing customer base. Investments into onboarding automation and customer success are helping accelerate activation and utilization. At the end of the first quarter, 301,000 customers were enabled for more than one solution, reflecting a 23% year-over-year growth. At the end of the first quarter, approximately 131,000 customers were actively utilizing more than one solution, reflecting a 32% year-over-year growth and an acceleration in growth compared to recent quarters. Over the trailing 12 months, net revenue retention was 95%, with multi-solution customers continuing to generate NRR above 100%. The slight reduction in reported NRR was impacted by declining third-party partner revenue within our legacy payments business. We continue to put much of our focus and investment on our fastest-growing solutions, and we continue to see outsized payments revenue growth in these top 6 solutions. In these top 6 solutions, TPV grew 19.8% year-over-year and now represents 35% of total TPV, up from 30% in the first quarter of 2025. Top solution payments revenue grew 10% year-over-year, now representing over 46.5% of total payments revenue. Highlighting the payment performance in our growth solutions is important because this is where we're focusing our investments. The improvements in cross-sell metrics I highlighted a moment ago are largely due to the gains of our top 6 solutions. The remainder of our payments business drives meaningful cash flow generation and a lower growth. As a reminder, we report payments revenue on a net basis and therefore, incrementally contributes approximately 95% gross margin within our core solutions. As such, payments revenue growth is a meaningful contributor to our overall adjusted EBITDA margin expansion. Now I'll pass it over to Ryan, who will review our financial results in more detail as well as provide second quarter and full year 2026 guidance.
Ryan Siurek: Thanks, Eric. Total reported revenue in the first quarter was $147.5 million, up 3.6% from the prior year period. Subscription and transaction revenue, our primary recurring revenue base was $142.1 million. Pro forma revenue adjusted for the acquisition of ZyraTalk, which closed in Q3 2025, was $596 million on an LTM basis, an increase of 5.2% and $147.5 million for the quarter, an increase of 3%, both on a year-over-year basis. Adjusted gross profit in the quarter was $114.8 million, representing an adjusted gross margin of 77.8%. First quarter adjusted EBITDA was $40.7 million with an adjusted EBITDA margin of 27.6%. Now turning to adjusted operating expenses, which are reconciled in the appendix to this presentation. For the quarter, adjusted operating expenses were slightly higher year-over-year as a percentage of revenue, increasing from 46.5% to 50.3%, representing targeted growth investments across sales and marketing and product development, including the post-acquisition ZyraTalk costs. For the LTM period as a percentage of revenue, adjusted expenses were flat at 47.9%. Next, I'll turn to some key liquidity measures, which include cash flow from continuing operations. We continue to generate significant free cash flow as we invest to grow our business and invest in our AI-first products. It is important to note that the cash flow metrics shown on Slide 13 and that I'm about to discuss include the cash generated from the divested Marketing Technology Solutions business through October 31, 2025. And as such, year-over-year comparisons and quarterly trending are not fully comparable. Cash flow from operations for the quarter was $24.6 million as compared to the prior quarter of $21.3 million and the prior year of $30.7 million. As a reminder to our guidance last quarter, our first quarter is historically burdened by higher cash outflows as compared to other quarters. Levered free cash flow was $16.6 million for the quarter. And for the trailing 12-month period, we generated more than $71 million. Adjusted unlevered free cash flow was $25.3 million in the quarter and $121.6 million for the last 12 months. We ended the quarter with $129 million in cash and cash equivalents and $155 million of undrawn capacity on our revolver, which will step down to $125 million in July 2026. As of March 31, we have $525 million of debt outstanding. Our total net leverage as calculated for our credit facility was approximately 2.2x and continues to demonstrate our deleveraging from strong operational performance and free cash generation. We have $425 million of notional swaps at a weighted average rate of 3.91% that effectively hedge the floating rate component of our interest cost through October 2027. Our long-term debt does not mature until July 2031, while our undrawn revolver capacity provides availability through July 2030, providing us with runway and financial flexibility for the foreseeable future. In terms of capital allocation, in addition to our AI-first investments, in the first quarter, we repurchased approximately 1.3 million shares for $13.9 million at an average price of $11 per share. Based on the shares repurchased through March 31, 2026, we have approximately $33.9 million remaining in our total repurchase authorization of $300 million through the end of 2026. I would now like to finish by discussing our outlook for the second quarter and full year of 2026. For the second quarter of 2026, we expect total revenue of $150.5 million to $153.5 million and adjusted EBITDA of $41 million to $43 million. For the full year 2026, we reiterate our previous guidance from mid-March and expect revenue of $612 million to $632 million and adjusted EBITDA of $183 million to $191 million. Operator, we are now ready to begin the question-and-answer session.
Operator: Our first question comes from the line of Bhavin Shah from Deutsche Bank.
Bhavin Shah: One for Eric or Matt and then one follow-up for Ryan. Eric or Matt, it was great to see that customer example leveraging ZyraTalk. Can you just maybe talk about where we are in terms of cross-selling ZyraTalk into the overall customer base? How are those conversations going? And how do you think about the time line of adoption of those customers that you think would best benefit from the solution?
Eric Remer: Thank you for the question. Matt, do you want to take...
Matthew Feierstein: Yes, I'll start. First of all, we're super excited about ZyraTalk. Meaningful head start for us in accelerating our AI road map, helped us move much faster from experimentation into embedded operational workflows. When you think about where we are, it's obviously much more than stand-alone AI voice as your question says. It's now a foundational capability that we're integrating into our customer-facing use cases through our systems of action. So already integrated with Service Fusion, actually, that happened ahead of schedule, already integrated with Briostack also ahead of schedule. And that's really enabling those workflows that connect the inbound demand that ZyraTalk is providing directly into our scheduling, job creation and customer engagement. So customer reception has been great. We're also leveraging internally experimenting across areas like AI-driven surveys that support other parts of our product and our operation, outbound prospect engagement. So all in all, ZyraTalk as a platform has been everything we expected and more. And we're really ahead of pace relative to our integration, launch and customer acquisition goals through Q1. And we continue to see really interesting use cases for AI-enabled workflow automation, which is becoming increasingly more important to our customers.
Bhavin Shah: Great. And looking forward to seeing more in the coming quarters. Maybe, Ryan, just for you. Just by your math, looking at subscription and transaction growth, if you exclude the legacy payment solutions, it appears growth remains healthier than just the reported number. Can you maybe just help us understand some of the underlying assumptions that's going into the full year guide in terms of how much of a drag the legacy payments line item is having on the overall business? Is the 1Q growth rate is a reasonable way to think about the rest of the year? Or should we think about it differently?
Ryan Siurek: Yes. Thanks, Bhavin, for the question. I appreciate it. I think you can tell from the full year guide that remained unchanged. We're expecting continued growth throughout the year, particularly in the back half of the year, given the Q2 guide that we just came out with. We understand in our -- from our perspective, the focus on the second half acceleration that's embedded in the guide. And to be clear, like we're focused on it. We have confidence though in some particular areas for the back half of the year in particular. First, pricing actions are going to have a larger impact in the back half based on the timing and the rollout cadence of those pricing actions to our overall portfolio, which isn't just one solution, various solutions in our portfolio. The second is, as Matt talked about and some of the examples provided, we're seeing improving leading indicators across payments enablement, multiproduct adoption and really growth in top solutions. So while we do have some of the legacy portfolio drag, and we're not going to give guidance with regard to the split between the top 6 solutions and the legacy portfolio, we do continue to expect growth in the top 6 solutions throughout the course of the year, particularly as we execute against some of the strategies I just talked about. Third, I would say that we've been making investments over the last 18 to 24 months particularly around our go-to-market structure, onboarding and execution. And we're moving really a lot of those from foundational elements into building for scaling purposes. And then finally, last but really not least in kind of those pillars, we're moving from AI investment into monetization of those targeted investments. The 2 examples, I think, that we gave on the call today highlight those and with products like EverHealth Scribe and the ZyraTalk integrations with AI reception is contributing incremental ARPU expansion and that just gives us further confidence that there's more opportunities. That will be multiyear, not just for this year, but we're continuing to grow those.
Operator: And our next question will come from the line of Alex Sklar from Raymond James.
Alexander Sklar: Maybe for Eric or Matt or Evan want to take this one, but I wanted to ask you on new customer velocity and some of the top of funnel trends. Any change in mix shift on where you're seeing the growth come from between self-service, direct or some of the other channels? And then as we think about pipeline generation in particular, how much has changed since you started operating EverPro and EverHealth a little bit more independently in terms of top of funnel?
Eric Remer: That's a great question. I actually think it makes sense to have both Evan and Matt give their view of the pipeline [ everyone is ] set up.
Evan Berlin: Yes. Thanks, Alex, for the question. I mean I think a couple of things. One, we continue to see strong demand. The environment is still healthy. We continue to see sales cycles trend down, and we've seen that really over the last, I'd say, 3 or 4 quarters in a really positive way. Some of that is better execution on our end. Some of it is the claim rate and the demand from the prospective customers for some of the features that we rolled out. I also think it's just better execution from our teams. I think from a funnel health perspective, we talked about this in March and I think in November as well, we started to shift more and more of our effort and our investment into outbound. And while that was historically kind of 1% or 2% of kind of new bookings, it's starting to be a healthier percentage. We actually overachieved in Q1 against our budget. We have a fairly aggressive growth targets across 2026, but really pleased with the progress that the team has been able to make both on capitalizing on the demand environment as well as kind of the more aggressive mix to outbound, which we think over time has just better economics in terms of LTV to CAC.
Matthew Feierstein: Yes. And I'd follow on, Evan. Obviously, from an EverPro perspective, we're super focused from an inbound perspective. I think our demand trend remains healthy and stable. Sales cycle timing remained stable. Funnel health is obviously an area that we focus on all the time in terms of improving conversion through our marketing and sales motion. So just continued stability quarter-over-quarter from an EverPro standpoint.
Eric Remer: And I think the one question you asked, which is a great one, how has that shifted? With kind of the -- over the last year plus of kind of really separating EverHealth and EverPro, I think the funnel has never changed. I think during the transition, as Evan brought up, we had executionally making that transition. There were challenges within the execution as you've seen and the reacceleration that we're excited and very confident about is really driven by having both EverPro and EverHealth businesses much more mature at this point.
Alexander Sklar: Okay. I appreciate all the color there. Ryan, maybe just following up on the second half guide question, but from the margin side of things, there's a pretty big implied step-up in incremental margins. Where is the leverage coming from on the OpEx side in particular?
Eric Remer: We continue to just work through the transformation optimizations that we started with previously. I would say that a lot of the enhancement from an EBITDA perspective in the back half of the year is really going to be targeted from a flow-through perspective on the margin that's coming from the incremental revenue. So that incremental revenue is in areas where we have higher margin capabilities. The pricing impacts that I talked about earlier will have an outsized impact from a margin contribution perspective. Not only that, but we are also continuing to focus our efforts on the continued transformation optimization and cost optimizations that we have in various parts of the business. But we'll not underinvest. As you can see from a capitalization perspective and where we're spending time and effort from an investment point of view. If you look at an LTM basis, we're continuing to strongly invest in the areas that are providing the examples that Matt and Evan talked about from an AI perspective, we've increased our investment in capitalization from a software perspective, which is largely infrastructure as well as product capabilities by like $13 million year-over-year on an LTM basis. And we're going to continue to focus that resource allocation in a way that is going to continue to drive future growth for those higher-margin products.
Operator: Our next question will come from the line of Bill McNamara from Evercore ISI.
William McNamara: It's Bill on for Kirk. I guess how are you thinking about the cadence of share repurchases in 2026? And I guess, particularly in the context of your broader capital allocation priorities?
Bradley Korch: Yes. I mean, this is Brad. Sorry. As we've discussed before, I mean, the share repurchase program is something that we're not going to comment on. It's on a schedule and it kind of runs independently of day-to-day decisions. But we continue to think that repurchasing our shares is a really accretive use of capital. And so that's why we upsized the program last fall, and we continue to be active there.
William McNamara: Appreciate it. And then in your customer example featuring the EverHealth AI Scribe alongside integrated payments for an orthopedic practice, how should we kind of think about the adoption trends among medical professionals? And then if I could just tack on a follow-up to that, would you say demand for automated note taking is still in the early innings? And what do you believe differentiates your solution in a competitive landscape?
Bradley Korch: Thanks, Phil. I appreciate the question. I mean I think just moving backwards, the differentiation is that we've got a great integrated solution. We have a very robust road map across the rest of the year, and we have a significant base of customers to sell that integrated product that in terms of demand and need. From an efficiency gain perspective, we see that basically all of our provider customers at the SMB end of the market are going to need an integrated solution. So we see the opportunity as being very large. When you think about kind of ARPU expansion kind of to your first question, if you look at Scribe like an average payments customer, you're talking about acceleration in ARPU of nearly 100% if we add both of those products and kind of attach full share of wallet on the payment side. So it doubles the customer ARPU over a period of time. And when you think about kind of the growth algorithm for EverHealth getting -- and Matt touched on this with Service Fusion and ZyraTalk, getting customers to buy DrChrono or CollaborateMD and then attach payments and attach Scribe over a period of time give us a huge opportunity to accelerate revenue from existing customers.
Operator: I'm not showing any further questions at this time. I would now like to turn it back over to Eric Remer for any closing remarks.
Eric Remer: Thank you again for joining our call today. We remain focused on executing our strategy, which we believe positions us well for sustainable long-term growth and shareholder value creation. I'd like to thank our investors for their continued support and all of the EverCommerce employees for their hard work. Operator, this concludes our call.
Operator: Thank you for your participation in today's conference. This does conclude the program. You may now disconnect. Everyone, have a great day.